STADA seeks to strengthen its equity base
09/22/2003 . Press Release
The executive board of STADA Arzneimittel AG resolved today, with the approval of the supervisory board, to effect an increase of the share capital this year with an anticipated value of EUR 250 to 350 million, to strengthen its equity base. STADA intends to use the proceeds from the capital increase to finance further internal and external growth, for the partial repayment of liabilities and for general business purposes within STADA Arzneimittel AG and the Group.
“The planned capital increase will provide STADA with a strong equity base to also be able to participate in further development possibilities on the markets in the future, in particular, in our biggest core segment, generic products. With the option to choose the date of issue, we would like to utilise the currently favourable stock exchange environment for capital measures and to establish a sound basis for further continued and profit-oriented growth”, explained Hartmut Retzlaff, CEO STADA Arzneimittel AG.
Deutsche Bank AG, in its capacity as the Global Coordinator, will render assistance in effecting the capital increase.
The capital increase is intended to comprise of two tranches. The first tranche comprising of 5,000,000 new shares is intended to be effected as a capital increase with a subscription right of the shareholders in the ratio 4:1. Subject to the final approval of executive board and supervisory board, it is currently intended to offer the shares for subscription during the period from September 30 through October 13, 2003. Within the framework of the capital increase, excluding subscription rights, in the second tranche, up to approximately 1,680,000 new shares of STADA Arzneimittel AG are intended to be placed with investors within Germany and abroad. In addition, the banks will be granted an over-allotment option (Greenshoe) of up to an additional 186,000 new shares.
In relation to the choice of the issue structure, STADA CFO Wolfgang Jeblonski commented: “The capital increase with subscription rights provides our existing shareholders with the opportunity to continue participating fully in the potential appreciation of STADA shares. By effecting a capital increase excluding subscription rights, we would, in particular, like to give our international institutional investors the option of being part of the STADA success story.”
Details of the capital increase will be provided shortly before the issue and will be provided subject to the current market situation.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506